Can a drinkable vaccine stop Shigella's grip?
NCT ID NCT04242264
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial tests an experimental oral vaccine, WRSs2, designed to protect against Shigella sonnei, a common cause of severe diarrhea. Healthy adults aged 18-49 receive either the vaccine or a placebo, then are later exposed to the live bacteria in a controlled setting to see if the vaccine reduces the chance of getting sick. The study also checks how safe the vaccine is and how well the immune system responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an oral live-attenuated Shigella sonnei vaccine candidate called WRSs2
- What this could lead to
- If successful, this vaccine could help prevent shigellosis, a major cause of diarrheal disease, potentially reducing illness in travelers and communities where the infection is common.
- What could go wrong
- This is an early-phase trial with a small number of participants, and the vaccine may not provide strong protection or may cause side effects like diarrhea or vomiting, as seen in some initial participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNISATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States
-
The Hope Clinic of Emory University
Decatur, Georgia, 30030-1705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.